This article first appeared on GuruFocus .
Release Date: May 28, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Aurora Spine Corp ( ASAPF ) reported a gross profit margin of 62.6% for Q1 2026, an improvement of 460 basis points from the previous year.
-
The company has successfully launched new products, including the DEXA-L and Apollo plate, which are expected to drive growth.
-
Aurora Spine Corp ( ASAPF ) has expanded its sales team, adding five new salespeople, with plans to increase the sales force by 50% this year.
-
The issuance of a fourth US patent related to the DEXA technology platform strengthens the company's intellectual property portfolio.
-
The Silo platform, particularly the TFX product, continues to be a major contributor to revenues, with plans for product extensions to enhance offerings.
Negative Points
-
Q1 2026 revenues were relatively flat, with only a 0.4% increase compared to the same quarter last year.
-
The company faced a slower start to the year due to weather-related issues and market pricing pressures.
-
Aurora Spine Corp ( ASAPF ) anticipates that Q2 revenues may be in line or slightly lower than the previous year.
-
There are ongoing challenges in the adoption and stickiness of their products among physicians, impacting growth.
-
The company is still working through legal issues related to the TFX product and FDA discussions regarding the facet product.
Q & A Highlights
Q: What will it take for Aurora Spine to achieve a 15% to 20% year-over-year sales increase? A: Trent Northcutt, President and CEO, explained that achieving this growth will require finding the right regional sales directors and ensuring they can execute plans effectively. The company is focused on hiring individuals with relevant market experience and has recently added three new salespeople to cover previously underperforming or uncovered regions. Matt Goldstone, Chief Commercial Officer, added that expanding into new territories with more salespeople will drive new revenue opportunities.
Q: Is there an issue with the adoption and stickiness of Aurora Spine's products among doctors? A: Matt Goldstone, Chief Commercial Officer, stated that while there are many new products that might distract physicians, the clinical success of Aurora's portfolio ensures its stickiness. The company receives positive feedback from physicians about patient outcomes, which drives continued success. Trent Northcutt added that the minimally invasive procedures market is still developing, and interventional doctors are gradually adopting these new procedures.
Q: What are the growth drivers for Aurora Spine in 2026, especially with the facet product not being marketed currently? A: Matt Goldstone highlighted the maturing spinal portfolio, particularly the DEXA-C and DEXA-L products, as key growth drivers. The reintroduction of the Apollo plate enhances procedural solutions, making sales opportunities stronger. Trent Northcutt mentioned the upcoming release of a lateral oblique product for the SI joint market, which is expected to be a significant growth driver.
Q: Can you provide an update on the status of the facet product with the FDA? A: Trent Northcutt stated that the facet product is still FDA approved and the company is in discussions with the FDA to address some questions. The process may involve additional biomechanical testing, but there is no bad news, and progress is being made with the help of high-end FDA consultants.
Q: How is the legal issue with the TFX product progressing? A: Trent Northcutt mentioned that progress is being made on resolving the legal issue with the TFX product, and he is optimistic about reaching a resolution, although it is progressing on a monthly basis.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
